These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18645005)

  • 21. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    An J; Sun Y; Fisher M; Rettig MB
    Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas.
    Wolf JS; Chen Z; Dong G; Sunwoo JB; Bancroft CC; Capo DE; Yeh NT; Mukaida N; Van Waes C
    Clin Cancer Res; 2001 Jun; 7(6):1812-20. PubMed ID: 11410524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Li C; Johnson DE
    Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
    Jia L; Gopinathan G; Sukumar JT; Gribben JG
    PLoS One; 2012; 7(2):e32584. PubMed ID: 22393418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
    Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines.
    Ondrey FG; Dong G; Sunwoo J; Chen Z; Wolf JS; Crowl-Bancroft CV; Mukaida N; Van Waes C
    Mol Carcinog; 1999 Oct; 26(2):119-29. PubMed ID: 10506755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib inhibits human osteoclastogenesis.
    von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
    Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
    Momose I; Tatsuda D; Ohba S; Masuda T; Ikeda D; Nomoto A
    Cancer Sci; 2012 Sep; 103(9):1730-6. PubMed ID: 22676179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.